Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CSTL
#2185
Castle Biosciences, Inc. Common Stock
29.570
0
-3.05%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-3.05%
Monthly Change
-30.88%
6 month change
+20.13%
Cambio anual
+20.13%
Cierres anteriores
30.500
0
Open
29.570
0
Bid
Ask
Low
29.570
0
High
29.570
0
Volumen
98
Markets
Acciones
Atención Sanitaria
CSTL
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
24.98 M
25.41 M
26.58 M
27.45 M
28.51 M
29.73 M
—
Valuation ratios
Enterprise value
1.27 B
759.72 M
482.49 M
504 M
640.2 M
1.04 B
2.62 B
Price to earnings ratio
-124.35
-34.57
-8.83
-10.26
42.98
-46.87
-261.18
Price to sales ratio
20.29
11.45
4.33
2.68
2.35
—
—
Price to cash flow ratio
128.85
56.77
14.25
104.62
12.02
17.52
46.71
Price to book ratio
3.06
2.62
1.49
1.5
1.71
2.39
3.41
Enterprise value to EBITDA ratio
-178.18
-20.69
-5.97
-9.04
26.04
—
—
Profitability ratios
Return on assets %
0.02
0.07
0.15
0.13
0.03
0.04
0.05
Return on equity %
0.02
0.08
0.17
0.15
0.04
0.05
0.06
Return on invested capital %
214.6
318.99
226.88
171.67
17.63
79.98
90.61
Gross margin %
84.54
83.18
76.64
79.53
81.87
79.38
317.36
Operating margin %
10.44
42.6
53.16
30.93
2.61
12.44
49.26
EBITDA margin %
-11.35
-39.03
-58.93
-25.38
7.4
-0.63
-40.01
Net margin %
16.42
33.26
48.99
26.15
5.49
7.02
27.51
Liquidity ratios
Quick ratio
20.47
14.13
7.98
6.04
7.13
5.11
27.29
Current ratio
20.58
14.21
8.09
6.2
7.29
5.26
27.95
Inventory turnover
5.61
7.47
—
—
—
—
—
Asset turnover
0.22
0.21
0.3
0.49
0.67
0.62
0.64
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
—
0.02
0.02
0.07
Long term debt to total equity ratio
0
—
—
—
0.02
0.02
0.08
Per share metrics
Operating cash flow per share
0.52
0.76
1.6
0.21
2.22
2.22
2.21
EBIT per share
-0.45
-1.6
-3.5
-2.54
0.29
-1.48
-2.61
EBITDA per share
-0.38
-1.46
-3.1
-2.08
0.84
-0.08
-1.19
Total debt per share
—
—
—
—
—
—
—
Cash per share
21.65
13.11
9.93
9.07
15.95
16.64
65.28
Net current asset value per share
22.7
14.07
11.22
11.03
12.31
12.46
48.77
Tangible book value per share
21.96
12.84
10.47
10.22
11.95
12.81
49.93
Working capital per share
21.59
13.08
9.83
9.25
10.62
10.09
41.47
Book value per share
21.96
16.38
15.32
14.6
15.58
16.24
63.11
Noticias
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates
Castle Biosciences T4 2025: volúmenes de pruebas suben 42%, entra al mercado de DA
Castle Biosciences T4 2025: volumen de pruebas sube 42%, entra a mercado AD
Castle Biosciences Q4 2025 slides: test volumes surge 42%, enters AD market